RESI Boston 2026: Your Complete Conference Guide

September 15, 2026 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Life Science Nation (LSN) is pleased to release the RESI Boston 2026 Program Guide for the upcoming hybrid conference, taking place September 22–23 in person at the Westin Copley Place in Boston, followed by virtual partnering on September 25 and September 28–29.

Held during Biotech Week Boston, RESI brings together early-stage life science companies, active investors, strategic partners, and industry leaders for targeted fundraising and business development conversations. The event features the Innovator’s Pitch Challenge, investor panels, workshops, company showcases, and RESI Partnering, the conference’s purpose-built platform for scheduling one-on-one meetings.

The Program Guide offers a comprehensive look at the RESI Boston agenda, including sessions focused on the Boston biotech ecosystem, therapeutic innovation, pharma partnering, strategic capital, health systems, chronic disease care, family office investing, and impact investing. Attendees can also explore the participating investor, sponsor, exhibitor, and company lineup, along with networking opportunities throughout the event.

With partnering underway and meeting calendars continuing to fill in the final weeks before the conference, RESI Boston offers innovators a valuable opportunity to connect directly with investors and strategic stakeholders shaping the future of healthcare.

View the program guide and register for RESI Boston today.

Meet the Investor Judges at RESI Boston 2026

September 15, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston brings together early-stage life science innovators and active investors during Biotech Week Boston. Life Science Nation is pleased to announce the investor judges participating in the Innovator’s Pitch Challenge (IPC).

This year’s IPC will feature more than 70 companies presenting across 20 pitch sessions over two days, offering startups a valuable opportunity to gain visibility, present directly to investors, and receive real-time feedback from experienced decision-makers.

Each pitch session will be evaluated by a panel of investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Companies will deliver a six-minute presentation followed by seven minutes of live investor Q&A, giving judges the opportunity to assess scientific differentiation, commercial potential, and investment readiness.

All IPC companies will also have a dedicated space in the RESI Exhibition Hall, creating additional opportunities for follow-up conversations and deeper engagement with investors and conference attendees.

RESI Boston attendees will be invited to vote with their RESI Cash for their favorite presenting companies. The Top 3 companies will be announced, with winners receiving prizes and additional exposure through the LSN Newsletter.

See the investors serving as judges for this year’s RESI Boston Innovator’s Pitch Challenge:

Featured RESI Boston IPC Judge
René Bastón Covenant Venture Capital	Caleb Bell Beyond Next Ventures	Randy Berholtz Mesa Verde Venture Partners
Shailesh Chavan Ingenious Global Venture Partners	Bruce Cohen Xeraya Capital	Yvette Ferreira Xcellerant Ventures
Navin Govind Evidence Ventures	Ole Henrik Bang Andreasen Avant Bio	Christopher Hupp Ipsen S.A.
Deepak Jha Autobahn Labs	James Lee Unistone Ventures	Claire Leurent AbbVie Ventures
Heather Loring AstraZeneca	James Massaquoi Glasswing Ventures	Mahesh Narayanan Neuvation Ventures
John Pennett Mid Atlantic Bio Angels	Garrett Peterson Yahara Ventures	Andrew Rae Woodgreen Ventures
Raza Shaikh Launchpad Venture Group	Justin Siemann Sontag Foundation	Sarah Tao CSL Behring
Martin Taylor F-Prime Capital	Lily Ting Lundbeck	Sally Wang Liang Xpanse Venture

RESI Boston Investor Speakers

September 9, 2026September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston brings together active early-stage investors and life science innovators for two days of investor-led programming focused on capital, partnering, and market dynamics shaping healthcare innovation.

The agenda will feature leading biotech VCs, family offices, corporate scouts, health system investors, and impact-focused investors sharing how they evaluate opportunities, where they see momentum, and what founders need to understand as they prepare to raise capital and build strategic partnerships.

From Boston’s biotech ecosystem and early-stage therapeutic investing to pharma partnering, health systems, strategic capital, chronic disease, women’s health, family offices, and impact investing, the panel program offers practical insight across the full life science financing landscape.

These conversations are designed to help entrepreneurs better understand investor priorities, refine their fundraising strategy, and build relationships with the people actively shaping the future of healthcare innovation.

RESI Boston takes place in person September 22–23 at the Westin Copley Place, with virtual partnering September 25 and September 28–29. Whether attending in Boston or virtually, participants can connect with investors, gain perspective from the panel stage, and advance their next conversations through targeted partnering.

Featured RESI Boston Investor Speakers
John Abeles Northlea Partners	Marc Appel Pacific Bridge NY	Farnaz Bakhshi ACS BrightEdge
Caleb Bell Beyond Next Ventures	Alan Chiu Breakthrough T1D	Scott Davis Sontag Foundation
Ronald Dorenbos BioFrontline Ltd.	Shane Duffy Avanos Medical, Inc.	Tao Fang MRL Ventures Fund (MRLV)
David Fogel Mass Medical Angels	Navin Govind Evidence Ventures	Nimisha Gupta Jazz Pharmaceuticals, Inc
William Hsu, PhD NuFund Venture Group	Austin Hwang Analog Garage	Jonathan Ilicki Industrifonden
Renaud Jacquemart Omnium Global	Rohit Jain HBS Alumni Angels of Northern California	Satoshi Konagai Astellas Venture Management (AVM)
Jason Kraus Boston Harbor Angels	Kathy Ku Sazze Partners	Sally Wang Liang Xpanse Venture
Nate Macht ACS BrightEdge	Nune Martiros Paladin Capital Group	Andrew Merken Polsinelli PC
Nikhil Mutyal AstraZeneca	Rohit Nuwal TELUS Ventures	Maggie O'Toole LabCentral
Soyoung Park 1004 Venture Partners	Dushyant Pathak Autobahn Labs	Garrett Peterson Yahara Ventures
Andrew Rae Woodgreen Ventures	Parthiban Rajasekaran Sanofi	Armin Rump Otsuka Pharmaceutical Co., Ltd.
Mo Soleja Golden Seeds	Yvanka de Soysa Foreground Capital	Daniel Teper YADAY Health
Andrew Thomson Ipsen S.A.	John Tremblay Launchpad Venture Group	Le Zhan Yunion Healthcare Ventures

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

Life Science Nation’s 2027 RESI conference calendar will connect early-stage life science companies with global investors, pharma partners, and industry leaders across four major life science hubs: San Francisco, Tokyo, Philadelphia, and Boston.

The year begins during JPM week and continues through Asia, BIO International Convention week in Philadelphia, and Boston’s biotech week in September. Each event is designed to help emerging companies build the investor relationships and strategic partnerships needed to move their companies forward.

RESI JPM 2027: January 11–12

San Francisco Marriott Marquis, San Francisco

Registration is now open for RESI JPM 2027.

Held concurrently with JPM Healthcare Week, RESI JPM brings early-stage companies into San Francisco during one of the world’s largest annual gatherings for healthcare investment and business development. The two-day in-person conference will be followed by virtual partnering on January 13, 18, and 19.

Previous RESI JPM conferences have drawn more than 1,000 attendees, including over 600 early-stage life science investors, innovators, and industry experts. For companies raising capital, pursuing strategic partnerships, or preparing for a major financing milestone, RESI offers a focused setting to make the most of the week.

RESI Asia Japan 2027: April 13

ANA InterContinental, Tokyo

RESI Asia Japan launches in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster.

Japan represents one of the life science industry’s most valuable and least accessible markets. Its leading pharmaceutical companies are active licensors and acquirers of external innovation, while the country offers deep clinical development capabilities and a progressive regulatory pathway for regenerative medicine, cell therapy, and gene therapy.

RESI Asia Japan will create a direct bridge between Japan’s world-class science ecosystem and global capital and partnering networks. The event is part of a broader collaboration between Life Science Nation and KBIC focused on strengthening commercialization pathways, entrepreneur education, capital formation, and international business development for Japanese life science companies.

RESI Philadelphia 2027: June 7

Convene, Philadelphia

RESI Philadelphia will take place during BIO International Convention week, complementing the broader industry activity in the city with a dedicated forum for early-stage companies and active investors.

Philadelphia is a leading center for cell and gene therapy, biopharma, medical innovation, and academic research. RESI provides companies and investors attending BIO week with a targeted environment for investor partnering, live pitch opportunities, and conversations that can turn promising science into fundable, strategic opportunities.

Virtual partnering dates will be announced soon.

RESI Boston 2027: September 22

Westin Copley Place, Boston

RESI returns to Boston during biotech week, bringing the global early-stage life science investment community together in one of the world’s most important innovation hubs.

Boston’s unmatched concentration of founders, investors, academic institutions, biotech companies, and strategic partners makes it an essential stop on the RESI calendar. The in-person event will offer targeted partnering, investor panels, educational programming, and the Innovator’s Pitch Challenge for companies seeking to raise visibility and advance fundraising conversations.

Virtual partnering dates will be announced soon.

A Global RESI Run

The 2027 lineup offers companies multiple opportunities throughout the year to engage the Life Science Nation network, deepen relationships with investors and strategic partners, and access new regional markets.

RESI JPM: January 11–12, San Francisco
RESI Asia Japan: April 13, Tokyo
RESI Philadelphia: June 7, Philadelphia
RESI Boston: September 22, Boston

Registration is now open for RESI JPM 2027. Register by October 2 to save $900 with Super Early Bird pricing. Learn more at resiconference.com.

RESI Boston 2026 Innovator’s Pitch Challenge Finalists

September 1, 2026September 1, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

The Innovator’s Pitch Challenge (IPC) showcases early-stage companies developing breakthrough technologies across key sectors of life science and returns to RESI Boston with more than 65 innovative companies selected to pitch across 20 sessions over two days, September 22–23, 2026.

Each finalist will present to panels of active life science investors and industry leaders in sector-focused sessions spanning biotech, medtech, diagnostics, digital health, and more. The program gives fundraising companies the opportunity to share their technologies, receive practical feedback, and connect directly with investors and strategic partners seeking new opportunities.

For attendees, IPC is a chance to discover emerging companies and hear directly from the founders behind them. Finalists will also be available throughout the event exhibiting, networking, and attendees participating in partnering can schedule one-on-one meetings to continue the conversation.

Join Life Science Nation at RESI Boston during Biotech Week for two full days of company pitches, investor insights, and targeted partnering.

Meet the RESI Boston Innovator’s Pitch Challenge Finalists:

Bayer Co.Lab Joins RESI Boston 2026 as Title Sponsor

September 1, 2026September 3, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to welcome Bayer Co.Lab as a Title Sponsor of RESI Boston 2026, taking place September 22-23 at the Westin Copley Place in Boston, with virtual partnering continuing September 25 and 28-29.

Bayer Co.Lab is Bayer’s global network of life science incubators supporting early-stage entrepreneurs developing breakthrough technologies. By connecting emerging companies with scientific expertise, mentorship, infrastructure, and Bayer’s broader global network, Co.Lab provides an environment designed to help innovators advance promising science and build the relationships needed for future growth.

Bayer Co.Lab’s mission is closely aligned with RESI’s focus on connecting early-stage life science and healthcare companies with investors, strategic partners, and industry leaders who can accelerate breakthrough therapies.

Bayer Co.Lab’s will be sponsoring a 2-hour session at RESI Boston 2026:

Connecting Asian Biotech Innovation with Global Partners: A Bayer Co.Lab Showcase

Tuesday, September 22, 2:00 – 4:00pm EST

The showcase will bring seven emerging biotechnology companies from Korea and Japan to the RESI stage, highlighting innovative approaches across various therapeutic modalities.

RSVP for Bayer Co.Lab Showcase

artiCure | Korea

Tumor-selective replicating gene therapy targeting solid tumors

Crafton Biotechnology | Japan

mRNA therapeutics supported by advanced computational approaches

Curigin | Korea

RNA-based therapeutic technologies across multiple disease areas

Elisigen | Korea

Next-generation gene therapy with programs in ophthalmology

Genome & Company | Korea

Microbiome-driven therapeutic discovery and development

ILIAS Biologics | Korea

Exosome-based therapeutics for inflammatory and fibrotic diseases

Kanjin Therapeutics | Japan

RNA therapeutics, including siRNA and antisense approaches, for areas of unmet medical need

The program reflects a growing opportunity to connect promising innovation emerging from Asian biotech ecosystems with global pharmaceutical partners, investors, and other strategic collaborators. By bringing Korean and Japanese companies directly into the RESI community, the showcase will create a forum for companies to present their science, build international relationships, and explore pathways for global development and partnership.

Meet Bayer at RESI Boston

Bayer will have a strong presence at RESI Boston, with senior representatives spanning Co.Lab and BD & Licensing departments.

Alberto Nobili Sr. Director, Strategy and Portfolio at Co.Lab	Nobuhiro Kazama Head of Collaborate to Cure Japan Hub	Ilona Gutcher Senior Director, BD&L Oncology
Carla Klattenhoff Senior Director / Scientific US Lead for Research and Early Development in CV, Renal and Immunology	Shivaranjani Sridharan Executive Director, Business Development & Licensing

Their participation gives RESI attendees an opportunity to engage with Bayer leaders representing multiple areas of scientific and strategic interest and to gain greater insight into how a global pharmaceutical company approaches external innovation and collaboration.

Bringing Global Innovators Together in Boston

RESI has always been built around a simple idea: great science can come from anywhere, but moving it forward requires the right connections.

Bayer Co.Lab’s participation as Title Sponsor of RESI Boston 2026 reinforces that mission. From supporting emerging entrepreneurs to creating new connections between Asian biotech innovators and the global life science ecosystem, the collaboration will bring another important dimension to this year’s RESI Boston.

Join Bayer Co.Lab and the global early-stage life science community at RESI Boston 2026!

Where Cross-Border Deal Flow Actually Happens

September 1, 2026September 1, 2026 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Every VC and PE firm says they want cross-border deal flow. Few have it. Most cross-border relationships stop at an introduction that never becomes a term sheet, because access without real syndicate standing on the other side rarely converts.

At RESI Boston 2026, Life Science Nation is convening a Cross-Border Investor Luncheon with Simon Hua, Chairman of BioMetas, to explore how cross-border access actually works through one of the hardest markets to enter.

Simon Hua
Chairman of BioMetas

Simon spent fifteen years in investment banking in Hong Kong, then a decade building and scaling the equity-for-service model that turns CRO relationships into equity stakes and syndicate seats, first at Viva Biotech, then ChemPartner, and now BioMetas. He has led CROs and his own fund, CFS Capital, to incubate and invest in over 100 innovative biotechs globally, while building an ecosystem with academic research institutions, government platforms, and VCs including Huagai Capital, E-Fund Capital, and Qiming Venture Partners.

The luncheon is built around a simple premise: bring together VCs and PE firms that want genuine syndicate relationships outside their own region, with funds that can send them deal flow and receive it in return.

Simon will speak directly to how that access works: how the equity-for-service model surfaces promising biotechs before they are broadly shopped, and how that early visibility converts into syndicate seats alongside the region’s leading investors.

Whether you are looking east or west, the practical question is the same:

How do you actually get inside?

RSVP for Cross-Border Investor Luncheon Today

*You must be an active VC investment firm that makes direct investments into life science and healthcare companies for us to approve your RSVP.